de Jong EK, Geerlings MJ, den Hollander AI. Age-related macular degeneration. Genetics and Genomics of Eye Illness: MA, USA: Elsevier; Tutorial Press, 2020. p. 155–80.
Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17:611–25.
Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling – accountable for vascular operate. Nat Rev Mol Cell Biol. 2006;7:359–71.
Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P. Position and therapeutic potential of VEGF within the nervous system. Physiol Rev. 2009;89:607–48.
Falavarjani KG, Nguyen QJE. Opposed occasions and problems related to intravitreal injection of anti-VEGF brokers: a assessment of literature. Eye (Lond). 2013;27:787–94.
Bakri SJ, Thorne JE, Ho AC, Ehlers JP, Schoenberger SD, Yeh S, et al. Security and efficacy of anti-vascular endothelial progress issue therapies for neovascular age-related macular degeneration: a report by the american academy of ophthalmology. Ophthalmology. 2019;126:55–63.
Meyer CH, Michels S, Rodrigues EB, Hager A, Mennel S, Schmidt JC, et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial issue injections. Acta Ophthalmol. 2011;89:70–5.
Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados IJR. Security of repeat intravitreal injections of bevacizumab versus ranibizumab: our expertise after 2000 injections. Retina. 2009;29:313–8.
Tolentino MJSoo. Systemic and ocular security of intravitreal anti-VEGF therapies for ocular neovascular illness. Surv Ophthalmol. 2011;56:95–113.
Colella P, Ronzitti G, Mingozzi F. Rising points in AAV-mediated in vivo gene remedy. Mol Ther Strategies Clin Dev. 2018;8:87–104.
Guimaraes TAC, Georgiou M, Bainbridge JWB, Michaelides M. Gene remedy for neovascular age-related macular degeneration: rationale, medical trials and future instructions. Br J Ophthalmol. 2021;105:151–7.
Arepalli S, Kaiser PK. Pipeline therapies for neovascular age associated macular degeneration. Int J Retina Vitreous. 2021;7:55.
Pecen PE, Kaiser PK. Present section 1/2 analysis for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2015;26:188–93.
He X, Cheng R, Benyajati S, Ma JX. PEDF and its roles in physiological and pathological situations: implication in diabetic and hypoxia-induced angiogenic illnesses. Clin Sci (Lond). 2015;128:805–23.
Rodrigues GA, Shalaev E, Karami TK, Cunningham J, Slater NK, Rivers HM. Pharmaceutical growth of AAV-based gene remedy merchandise for the attention. Pharm Res. 2019;36:29.
Naso MF, Tomkowicz B, Perry WL, Strohl WRJB. Adeno-associated virus (AAV) as a vector for gene remedy. BioDrugs. 2017;31:317–34.
Chen HJWJoMG. Adeno-associated virus vectors for human gene remedy. World J Med Genet. 2015;5:28–45.
Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, et al. Scientific protocol. An open-label, section I, single administration, dose-escalation examine of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther. 2001;12:2029–32.
Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, et al. Adenoviral vector-delivered pigment epithelium-derived issue for neovascular age-related macular degeneration: outcomes of a section I medical trial. Hum Gene Ther. 2006;17:167–76.
Rakoczy EP, Lai CM, Magno AL, Wikstrom ME, French MA, Pierce CM, et al. Gene remedy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 12 months follow-up of a section 1 randomised medical trial. Lancet. 2015;386:2395–403.
Constable IJ, Pierce CM, Lai CM, Magno AL, Degli-Esposti MA, French MA, et al. Section 2a Randomized Scientific Trial: Security and Publish Hoc Evaluation of Subretinal rAAV.sFLT-1 for Moist Age-related Macular Degeneration. EBioMedicine. 2016;14:168–75.
Campochiaro PA, Lauer AK, Sohn EH, Mir TA, Naylor S, Anderton MC, et al. Lentiviral Vector Gene Switch of Endostatin/Angiostatin for Macular Degeneration (GEM) Research. Hum Gene Ther. 2017;28:99–111.
Binley Ok, Widdowson PS, Kelleher M, de Belin J, Loader J, Ferrige G, et al. Security and biodistribution of an equine infectious anemia virus-based gene remedy, RetinoStat((R)), for age-related macular degeneration. Hum Gene Ther. 2012;23:980–91.
Kumar-Singh R. The function of complement membrane assault complicated in dry and moist AMD – From speculation to medical trials. Exp Eye Res. 2019;184:266–77.
Cashman SM, Ramo Ok, Kumar-Singh R. A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a mannequin of age associated macular degeneration. PLoS ONE. 2011;6:e19078.
Czajkowsky DM, Hu J, Shao Z, Pleass RJ. Fc‐fusion proteins: new developments and future views. EMBO Mol Med. 2012;4:1015–28.
Rath T, Baker Ok, Dumont JA, Peters RT, Jiang H, Qiao S-W, et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and simpler therapeutics. Crit Rev Biotechnol. 2015;35:235–54.
Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2018;9:15–32.
Kim HS, Kim I, Zheng L, Vernes J-M, Meng YG, Spiess C, editors. Evading pre-existing anti-hinge antibody binding by hinge engineering. MAbs. 2016;8:1536–47.
Huang T, Mathieu M, Lee S, Wang X, Kee YS, Bevers JJ, et al. Molecular characterization of human anti-hinge antibodies derived from single-cell cloning of regular human B cells. J Biol Chem. 2018;293:906–19.
Yan B, Boyd D, Kaschak T, Tsukuda J, Shen A, Lin Y, et al. Engineering higher hinge improves stability and effector operate of a human IgG1. J Biol Chem. 2012;287:5891–7.
Saunders KO. Conceptual Approaches to Modulating Antibody Effector Capabilities and Circulation Half-Life. Entrance Immunol. 2019;10:1296.
D’Eall C, Pon RA, Rossotti MA, Krahn N, Spearman M, Callaghan D, et al. Modulating antibody‐dependent mobile cytotoxicity of epidermal progress issue receptor‐particular heavy‐chain antibodies via hinge engineering. J Immunol. 2019;177:1129–38.
Dall’Acqua WF, Cook dinner KE, Damschroder MM, Woods RM. Wu HJTJoI. Modulation of the effector features of a human IgG1 via engineering of its hinge area. J Immunol. 2006;177:1129–38.
Pechan P, Rubin H, Lukason M, Ardinger J, DuFresne E, Hauswirth WW, et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther. 2009;16:10–6.
Bagley RG, Kurtzberg L, Weber W, Nguyen T-H, Roth S, Krumbholz R, et al. sFLT01: a novel fusion protein with antiangiogenic exercise. Mol Most cancers Ther. 2011;10:404–15.
Yang S, Zhao J, Solar X. Resistance to anti-VEGF remedy in neovascular age-related macular degeneration: a complete assessment. Drug Des Devel Ther. 2016;10:1857–67.
Lukason M, DuFresne E, Rubin H, Pechan P, Li Q, Kim I, et al. Inhibition of choroidal neovascularization in a nonhuman primate mannequin by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther. 2011;19:260–5.
Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, et al. Intravitreous injection of AAV2-sFLT01 in sufferers with superior neovascular age-related macular degeneration: a section 1, open-label trial. Lancet. 2017;390:50–61.
Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, de Vos AMJC. Crystal construction at 1.7 Å decision of VEGF in complicated with area 2 of the Flt-1 receptor. Cell. 1997;91:695–704.
Davari M, Soheili Z-S, Samiei S, Sharifi Z, Pirmardan ER. Overexpression of miR-183/-96/-182 triggers neuronal cell destiny in Human Retinal Pigment Epithelial (hRPE) cells in tradition. Biochem Biophys Res Commun. 2017;483:745–51.
Šali AJCOiB. Modelling mutations and homologous proteins. Curr Opin Biotechnol. 1995;6:437–51.
Bagley RG, Kurtzberg L, Weber W, Nguyen TH, Roth S, Krumbholz R, et al. sFLT01: a novel fusion protein with antiangiogenic exercise. Mol Most cancers Ther. 2011;10:404–15.
Kingsley LJ, Brunet V, Lelais G, McCloskey S, Milliken Ok, Leija E, et al. Growth of a digital actuality platform for efficient communication of structural knowledge in drug discovery. J Mol Graph Mannequin. 2019;89:234–41.
Laskowski R, MacArthur M, Thornton J. PROCHECK: validation of protein-structure coordinates. Worldwide Tables for Crystallography. 2012;684–7.
Wiederstein M, Sippl MJ. ProSA-web: interactive internet service for the popularity of errors in three-dimensional constructions of proteins. Nucleic Acids Res. 2007;35:W407–W10.
Sippl MJ. Recognition of errors in three‐dimensional constructions of proteins. Proteins. 1993;17:355–62.
Abraham MJ, Murtola T, Schulz R, Pá ll S, Smith JC, Hess B, et al. GROMACS: Excessive efficiency molecular simulations via multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1–2:19–25.
Bjelkmar P, Larsson P, Cuendet MA, Hess B, Lindahl E. Implementation of the CHARMM Pressure Area in GROMACS: Evaluation of Protein Stability Results from Correction Maps, Digital Interplay Websites, and Water Fashions. J Chem Concept Comput. 2010;6:459–66.
Berendsen H, Grigera J, Straatsma T. The lacking time period in efficient pair potentials. J Phys Chem. 1987;91:6269–71.
Hess B. P-LINCS: a parallel linear constraint solver for molecular simulation. J Chem Concept Comput. 2008;4:116–22.
Hess B, Bekker H, Berendsen HJ, Fraaije JG. LINCS: a linear constraint solver for molecular simulations. J Comput Chem. 1997;18:1463–72.
Zambrano R, Jamroz M, Szczasiuk A, Pujols J, Kmiecik S, Ventura S. AGGRESCAN3D (A3D): server for prediction of aggregation properties of protein constructions. Nucleic Acids Res. 2015;43:W306–13.
Kuriata A, Iglesias V, Pujols J, Kurcinski M, Kmiecik S, Ventura S. Aggrescan3D (A3D) 2.0: prediction and engineering of protein solubility. Nucleic Acids Res. 2019;47:W300–W7.
Ali M, Pandey RK, Khatoon N, Narula A, Mishra A, Prajapati VK. Exploring dengue genome to assemble a multi-epitope primarily based subunit vaccine by using immunoinformatics strategy to battle in opposition to dengue an infection. Sci Rep. 2017;7:9232.
Hajighahramani N, Nezafat N, Eslami M, Negahdaripour M, Rahmatabadi SS, Ghasemi Y. Immunoinformatics evaluation and in silico designing of a novel multi-epitope peptide vaccine in opposition to Staphylococcus aureus. Infect Genet Evol. 2017;48:83–94.
Solanki V, Tiwari V. Subtractive proteomics to establish novel drug targets and reverse vaccinology for the event of chimeric vaccine in opposition to Acinetobacter baumannii. Sci Rep. 2018;8:9044.
Saadi M, Karkhah A, Nouri HR. Growth of a multi-epitope peptide vaccine inducing sturdy T cell responses in opposition to brucellosis utilizing immunoinformatics primarily based approaches. Infect Genet Evol. 2017;51:227–34.
Meza B, Ascencio F, Sierra-Beltran AP, Torres J, Angulo C. A novel design of a multi-antigenic, multistage and multi-epitope vaccine in opposition to Helicobacter pylori: an in silico strategy. Infect Genet Evol. 2017;49:309–17.
Chauhan V, Rungta T, Goyal Ok, Singh MP. Designing a multi-epitope primarily based vaccine to fight Kaposi Sarcoma using immunoinformatics strategy. Sci Rep. 2019;9:2517.
Rana A, Akhter Y. A multi-subunit primarily based, thermodynamically steady mannequin vaccine utilizing mixed immunoinformatics and protein construction primarily based strategy. Immunobiology. 2016;221:544–57.
Dhanda SK, Usmani SS, Agrawal P, Nagpal G, Gautam A, Raghava GPS. Novel in silico instruments for designing peptide-based subunit vaccines and immunotherapeutics. Transient Bioinform. 2017;18:467–78.
Bhatnager R, Bhasin M, Arora J, Dang AS. Epitope primarily based peptide vaccine in opposition to SARS-COV2: an immune-informatics strategy. J Biomol Struct Dyn. 2021;39:5690–705.
Alam A, Khan A, Imam N, Siddiqui MF, Waseem M, Malik MZ, et al. Design of an epitope-based peptide vaccine in opposition to the SARS-CoV-2: a vaccine-informatics strategy. Transient Bioinform. 2021;22:1309–23.
Scussel R, Feuser PE, Luiz GP, Galvani NC, Fagundes MI, Goncalves Dal-Bo A, et al. Peptide-Built-in Superparamagnetic Nanoparticles for the Identification of Epitopes from SARS-CoV-2 Spike and Nucleocapsid Proteins. ACS Appl Nano Mater. 2022;5:642–53.
Shah I, Jamil S, Rehmat S, Butt HA, Ali SS, Idrees M, et al. Analysis and identification of important therapeutic proteins and vaccinomics strategy in direction of multi-epitopes vaccine designing in opposition to Legionella pneumophila for immune response instigation. Comput Biol Med. 2022;143:105291.
Ojha R, Gurjar Ok, Ratnakar TS, Mishra A, Prajapati VK. Designing of a bispecific antibody in opposition to SARS-CoV-2 spike glycoprotein focusing on human entry receptors DPP4 and ACE2. Hum Immunol. 2022;83:346–55.
Ismail S, Waheed Y, Ahmad S, Ahsan O, Abbasi SW, Sadia Ok. An in silico examine to unveil potential medicine and vaccine chimera for HBV capsid meeting protein: mixed molecular docking and dynamics simulation strategy. J Mol Mannequin. 2022;28:51.
Khan A, Khan S, Saleem S, Nizam-Uddin N, Mohammad A, Khan T, et al. Immunogenomics guided design of immunomodulatory multi-epitope subunit vaccine in opposition to the SARS-CoV-2 new variants, and its validation via in silico cloning and immune simulation. Comput Biol Med. 2021;133:104420.
Saha S, Raghava GPS. AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res. 2006;34:W202–W9.
Saha CK, Mahbub Hasan M, Saddam Hossain M, Asraful Jahan M, Azad AK. In silico identification and characterization of widespread epitope-based peptide vaccine for Nipah and Hendra viruses. Asian Pac J Trop Med. 2017;10:529–38.
Nguyen TL, Lee Y, Kim H. Immunogenic Epitope-Primarily based Vaccine Prediction from Floor Glycoprotein of MERS-CoV by Deploying Immunoinformatics Strategy. Int J Pept Res Ther. 2022;28:77.
Yazdani Z, Rafiei A, Valadan R, Ashrafi H, Pasandi M, Kardan M. Designing a potent L1 protein-based HPV peptide vaccine: a bioinformatics strategy. Comput Biol Chem. 2020;85:107209.
Ghosh P, Bhakta S, Bhattacharya M, Sharma AR, Sharma G, Lee SS, et al. A Novel Multi-Epitopic Peptide Vaccine Candidate In opposition to Helicobacter pylori: In-Silico Identification, Design, Cloning and Validation By Molecular Dynamics. Int J Pept Res Ther. 2021;27:1149–66.
Naqvi STQ, Yasmeen M, Ismail M, Muhammad SA, Nawazish IHS, Ali A, et al. Designing of Potential Polyvalent Vaccine Mannequin for Respiratory Syncytial Virus by System Stage Immunoinformatics Approaches. Biomed Res Int. 2021;2021:9940010.
Selvaraj G, Kaliamurthi S, Peslherbe GH, Wei DQ. Are the Allergic Reactions of COVID-19 Vaccines Attributable to mRNA Constructs or Nanocarriers? Immunological Insights. Interdiscip Sci. 2021;13:344–7.
Ashik AI, Hasan M, Tasnim AT, Chowdhury MB, Hossain T, Ahmed S. An immunoinformatics examine on the spike protein of SARS-CoV-2 revealing potential epitopes as vaccine candidates. Heliyon. 2020;6:e04865.
Abd Albagi SO, Al-Nour MY, Elhag M, Tageldein Idris Abdelihalim A, Musa Haroun E, Adam, Essa ME, et al. A a number of peptides vaccine in opposition to COVID-19 designed from the nucleocapsid phosphoprotein (N) and Spike Glycoprotein (S) through the immunoinformatics strategy. Inform Med Unlocked. 2020;21:100476.
Sharma S, Solanki V, Tiwari V. Reverse vaccinology strategy to design a vaccine focusing on membrane lipoproteins of Salmonella typhi. J Biomol Struct Dyn. 2021:1–16.
Dimitrov I, Naneva L, Doytchinova I, Bangov I. AllergenFP: allergenicity prediction by descriptor fingerprints. Bioinformatics. 2014;30:846–51.
Abraham Peele Ok, Srihansa T, Krupanidhi S, Ayyagari VS, Venkateswarulu TC. Design of multi-epitope vaccine candidate in opposition to SARS-CoV-2: a in-silico examine. J Biomol Struct Dyn. 2021;39:3793–801.
Soltan MA, Elbassiouny N, Gamal H, Elkaeed EB, Eid RA, Eldeen MA, et al. In Silico Prediction of a Multitope Vaccine in opposition to Moraxella catarrhalis: Reverse Vaccinology and Immunoinformatics. Vaccines (Basel). 2021;9:1–13.
Sanami S, Zandi M, Pourhossein B, Mobini GR, Safaei M, Abed A, et al. Design of a multi-epitope vaccine in opposition to SARS-CoV-2 utilizing immunoinformatics strategy. Int J Biol Macromol. 2020;164:871–83.
Halimatul Munawaroh HS, Gumilar GG, Berliana JD, Aisyah S, Nuraini VA, Ningrum A, et al. In silico proteolysis and molecular interplay of tilapia (Oreochromis niloticus) pores and skin collagen-derived peptides for environmental remediation. Environ Res. 2022:113002.
Rahmat Ullah S, Majid M, Rashid MI, Mehmood Ok, Andleeb S. Immunoinformatics Pushed Prediction of Multiepitopic Vaccine In opposition to Klebsiella pneumoniae and Mycobacterium tuberculosis Coinfection and Its Validation through In Silico Expression. Int J Pept Res Ther. 2021;27:987–99.
Singh A, Thakur M, Sharma LK, Chandra Ok. Designing a multi-epitope peptide primarily based vaccine in opposition to SARS-CoV-2. Sci Rep. 2020;10:16219.
Adhikari UK, Tayebi M, Rahman MM. Immunoinformatics Strategy for Epitope-Primarily based Peptide Vaccine Design and Energetic Web site Prediction in opposition to Polyprotein of Rising Oropouche Virus. J Immunol Res. 2018;2018:6718083.
Zhou F, He S, Zhang Y, Wang Y, Solar H, Liu Q. Prediction and characterization of the T cell epitopes for the key soybean protein allergens utilizing bioinformatics approaches. Proteins. 2022;90:418–34.
Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP v.2–a server for in silico prediction of allergens. J Mol Mannequin. 2014;20:2278.
Venkatarajan MS, Braun W. New quantitative descriptors of amino acids primarily based on multidimensional scaling of a lot of bodily–chemical properties. Mol Modeling Ann. 2001;7:445–53.
Nyström Å, Andersson PM, Lundstedt T. Multivariate knowledge evaluation of topographically modified α‐melanotropin analogues utilizing auto and cross auto covariances (ACC). Quant Construction‐Exercise Relation. 2000;19:264–9.
Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP v. 2—a server for in silico prediction of allergens. J Mol Modeling. 2014;20:1–6.
Dimitrov I, Flower DR, Doytchinova I, editors. AllerTOP-a server for in silico prediction of allergens. BMC Bioinforma. 2013;14:1–9.
Lapinsh M, Gutcaits A, Prusis P, Publish C, Lundstedt T, Wikberg JE. Classification of G‐protein coupled receptors by alignment‐impartial extraction of principal chemical properties of major amino acid sequences. Protein Sc. 2002;11:795–805.
Dehghani B, Hashempour T, Hasanshahi Z. Utilizing immunoinformatics and structural approaches to design a novel HHV8 vaccine. Int J Peptide Res Ther. 2020;26:321–31.
Yazdani Z, Rafiei A, Valadan R, Ashrafi H, Pasandi M, Kardan M. Designing a potent L1 protein-based HPV peptide vaccine: a bioinformatics strategy. Comput Biol Chem. 2020;85:107209.
Nguyen TL, Lee Y, Kim H. Immunogenic Epitope-Primarily based Vaccine Prediction from Floor Glycoprotein of MERS-CoV by Deploying Immunoinformatics Strategy. Int J Peptide Res Ther. 2022;28:1–11.
Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protecting antigens, tumour antigens and subunit vaccines. BMC Bioinform. 2007;8:4.
Jyotisha, Singh S, Qureshi IA. Multi-epitope vaccine in opposition to SARS-CoV-2 making use of immunoinformatics and molecular dynamics simulation approaches. J Biomol Struct Dyn. 2020:1–17.
Karagoz IK, Munk MR, Kaya M, Ruckert R, Yildirim M, Karabas L. Utilizing bioinformatic protein sequence similarity to research if SARS CoV-2 an infection may trigger an ocular autoimmune inflammatory reactions? Exp Eye Res. 2021;203:108433.
Yadav S, Prakash J, Shukla H, Das KC, Tripathi T, Dubey VK. Design of a multi-epitope subunit vaccine for immune-protection in opposition to Leishmania parasite. Pathogens International Well being. 2020;114:471–81.
Kumar Pandey R, Ojha R, Mishra A, Kumar, Prajapati V. Designing B‐and T‐cell multi‐epitope primarily based subunit vaccine utilizing immunoinformatics strategy to manage Zika virus an infection. J Cell Biochem. 2018;119:7631–42.
Dey J, Mahapatra SR, Patnaik S, Lata S, Kushwaha GS, Panda RK, et al. Molecular Characterization and Designing of a Novel Multiepitope Vaccine Assemble In opposition to Pseudomonas aeruginosa. Int J Peptide Res Ther. 2022;28:1–19.
Yukeswaran L, Shreeranjana S, Subhashini T. Immunoinformatics Aided Multi-epitope Primarily based Vaccine Design In opposition to Crimean-Congo Virus. AIJR Abstracts. 2021:43.
Oprea M, Antohe F. Reverse-vaccinology technique for designing T-cell epitope candidates for Staphylococcus aureus endocarditis vaccine. Biologicals. 2013;41:148–53.
Kalita P, Padhi AK, Zhang KY, Tripathi T. Design of a peptide-based subunit vaccine in opposition to novel coronavirus SARS-CoV-2. Microbial Pathogenesis. 2020;145:104236.
Ponomarenko J, Bui HH, Li W, Fusseder N, Bourne PE, Sette A, et al. ElliPro: a brand new structure-based device for the prediction of antibody epitopes. BMC Bioinform. 2008;9:514.
Bhasin M, Raghava GP. Prediction of CTL epitopes utilizing QM, SVM and ANN strategies. Vaccine. 2004;22:3195–204.
Morris JH, Huang CC, Babbitt PC, Ferrin TE. structureViz: linking Cytoscape and UCSF Chimera. Bioinformatics. 2007;23:2345–7.
Doncheva NT, Klein Ok, Domingues FS, Albrecht M. Analyzing and visualizing residue networks of protein constructions. Tendencies Biochem Sci. 2011;36:179–82.
Brysbaert G, Lorgouilloux Ok, Vranken WF, Lensink MF. RINspector: a Cytoscape app for centrality analyses and DynaMine flexibility prediction. Bioinformatics. 2018;34:294–6.
Amitai G, Shemesh A, Sitbon E, Shklar M, Netanely D, Venger I, et al. Community evaluation of protein constructions identifies useful residues. J Mol Biol. 2004;344:1135–46.
Brysbaert G, Mauri T, Lensink MF. Evaluating protein constructions with RINspector automation in Cytoscape. F1000Res. 2018;7:563.
Kay P, Yang YC, Paraoan L. Directional protein secretion by the retinal pigment epithelium: roles in retinal well being and the event of age‐associated macular degeneration. J Cell Mol Med. 2013;17:833–43.
Pirmardan ER, Soheili Z-S, Samiei S, Ahmadieh H, Mowla SJ, Naseri M, et al. In Vivo Analysis of PAX6 Overexpression and NMDA Cytotoxicity to Stimulate Proliferation within the Mouse Retina. Sci Rep. 2018;8:17700.
DeCicco-Skinner KL, Henry GH, Cataisson C, Tabib T, Gwilliam JC, Watson NJ, et al. Endothelial cell tube formation assay for the in vitro examine of angiogenesis. J Vis Exp. 2014;91:e51312.
Faibish M, Shao RJ, Jove J. A Matrigel-based tube formation assay to evaluate the vasculogenic exercise of tumor cells. J Vis Exp. 2011;55:1–4.
Arnaoutova I, George J, Kleinman HK, Benton GJA. The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the artwork. Angiogenesis. 2009;12:267–74.
Fruttiger M. Growth of the mouse retinal vasculature: angiogenesis versus vasculogenesis. Make investments Ophthalmol Vis Sci. 2002;43:522–7.
Brown AS, Zhang M, Cucevic V, Pavlin CJ, Foster FS. In vivo evaluation of postnatal murine ocular growth by ultrasound biomicroscopy. Curr Eye Res. 2005;30:45–51.
Kowalczuk L, Touchard E, Omri S, Jonet L, Klein C, Valamanes F, et al. Placental progress issue contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathy. PLoS One. 2011;6:e17462.
Sandin S, Ofverstedt LG, Wikstrom AC, Wrange O, Skoglund U. Construction and adaptability of particular person immunoglobulin G molecules in answer. Construction. 2004;12:409–15.
Saphire EO, Stanfield RL, Crispin MD, Parren PW, Rudd PM, Dwek RA, et al. Contrasting IgG constructions reveal excessive asymmetry and adaptability. J Mol Biol. 2002;319:9–18.
Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody Construction and Perform: The Foundation for Engineering Therapeutics. Antibodies (Basel). 2019;8:1–80.
Moritz B, Stracke JO. Evaluation of disulfide and hinge modifications in monoclonal antibodies. Electrophoresis. 2017;38:769–85.
Reibaldi M, Pulvirenti A, Avitabile T, Bonfiglio V, Russo A, Mariotti C, et al. Pooled Estimates of Incidence of Endophthalmitis after Intravitreal Injection of Anti-Vascular Endothelial Progress Issue Brokers with and with out Topical Antibiotic Prophylaxis. Retina. 2018;38:1–11.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.
Bhavsar AR, Googe JM Jr. Stockdale CR, Bressler NM, Brucker AJ, Elman MJ, et al. Threat of endophthalmitis after intravitreal drug injection when topical antibiotics usually are not required: the diabetic retinopathy medical analysis community laser-ranibizumab-triamcinolone medical trials. Arch Ophthalmol. 2009;127:1581–3.
Bhatt SS, Stepien KE, Joshi Ok. Prophylactic antibiotic use after intravitreal injection: impact on endophthalmitis charge. Retina. 2011;31:2032–6.
Bhavsar AR, Ip MS, Glassman AR. Drcrnet, the SSG. The danger of endophthalmitis following intravitreal triamcinolone injection within the DRCRnet and SCORE medical trials. Am J Ophthalmol. 2007;144:454–6.
Kim SJ, Toma HS. Antimicrobial resistance and ophthalmic antibiotics: 1-year outcomes of a longitudinal managed examine of sufferers present process intravitreal injections. Arch Ophthalmol. 2011;129:1180–8.
Milder E, Vander J, Shah C, Garg S. Modifications in antibiotic resistance patterns of conjunctival flora as a consequence of repeated use of topical antibiotics after intravitreal injection. Ophthalmology. 2012;119:1420–4.
Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam WC. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119:1609–14.
Dall’Acqua WF, Cook dinner KE, Damschroder MM, Woods RM, Wu H. Modulation of the effector features of a human IgG1 via engineering of its hinge area. J Immunol. 2006;177:1129–38.
Valeich J, Boyd D, Kanwar M, Stenzel D, De Ghosh D, Ebrahimi A, et al. Taking the Hinge off: An Strategy to Effector-Much less Monoclonal Antibodies. Antibodies (Basel). 2020;9:1–14.
Stewart MW. The increasing function of vascular endothelial progress issue inhibitors in ophthalmology. Mayo Clin Proc. 2012;87:77–88.
Stewart MW, Grippon S, Kirkpatrick P. Aflibercept. Nat Rev Drug Discov. 2012;11:269–70.
He J, Wang H, Liu Y, Li W, Kim D, Huang H. Blockade of vascular endothelial progress issue receptor 1 prevents irritation and vascular leakage in diabetic retinopathy. J Ophthalmol. 2015;2015:605946.
Van Bergen T, Hu TT, Etienne I, Reyns GE, Moons L, Feyen JHM. Neutralization of placental progress issue as a novel remedy choice in diabetic retinopathy. Exp Eye Res. 2017;165:136–50.
Jiang B, Xu S, Hou X, Pimentel DR, Brecher P, Cohen RA. Temporal management of NF-kappaB activation by ERK differentially regulates interleukin-1beta-induced gene expression. J Biol Chem. 2004;279:1323–9.
Bonfiglio V, Platania CBM, Lazzara F, Conti F, Pizzo C, Reibaldi M, et al. TGF-beta Serum Ranges in Diabetic Retinopathy Sufferers and the Position of Anti-VEGF Remedy. Int J Mol Sci. 2020;21:1–16.
Tokunaga CC, Mitton KP, Dailey W, Massoll C, Roumayah Ok, Guzman E, et al. Results of anti-VEGF remedy on the restoration of the growing retina following oxygen-induced retinopathy. Investig Ophthalmol Vis Sci. 2014;55:1884–92.
Dolar-Szczasny J, Bucolo C, Zweifel S, Carnevali A, Rejdak R, Zaluska W, et al. Analysis of Aqueous Flare Depth in Eyes Present process Intravitreal Bevacizumab Remedy to Deal with Neovascular Age-Associated Macular Degeneration. Entrance Pharmacol. 2021;12:656774.
Montemagno C, Pages G. Resistance to Anti-angiogenic Therapies: A Mechanism Relying on the Time of Publicity to the Medication. Entrance Cell Dev Biol. 2020;8:584.
Gacche RN, Assaraf YG. Redundant angiogenic signaling and tumor drug resistance. Drug Resist Updat. 2018;36:47–76.
Latifi-Navid H, Soheili ZS, Samiei S, Sadeghi M, Taghizadeh S, Pirmardan ER, et al. Community evaluation and the influence of Aflibercept on particular mediators of angiogenesis in HUVEC cells. J Cell Mol Med. 2021;25:8285–99.
Rezzola S, Loda A, Corsini M, Semeraro F, Annese T, Presta M, et al. Angiogenesis-Irritation Cross Discuss in Diabetic Retinopathy: Novel Insights From the Chick Embryo Chorioallantoic Membrane/Human Vitreous Platform. Entrance Immunol. 2020;11:581288.
Haibe Y, Kreidieh M, El Hajj H, Khalifeh I, Mukherji D, Temraz S, et al. Resistance Mechanisms to Anti-angiogenic Therapies in Most cancers. Entrance Oncol. 2020;10:221.
Lazzara F, Fidilio A, Platania CBM, Giurdanella G, Salomone S, Leggio GM, et al. Aflibercept regulates retinal irritation elicited by excessive glucose through the PlGF/ERK pathway. Biochem Pharmacol. 2019;168:341–51.
Winterhoff B, Konecny GE. Focusing on fibroblast progress issue pathways in endometrial most cancers. Curr Probl Most cancers. 2017;41:37–47.
Chae YK, Ranganath Ok, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, et al. Inhibition of the fibroblast progress issue receptor (FGFR) pathway: the present panorama and boundaries to medical software. Oncotarget. 2017;8:16052–74.
Turner N, Grose R. Fibroblast progress issue signalling: from growth to most cancers. Nat Rev Most cancers. 2010;10:116–29.
Larrieu-Lahargue F, Welm AL, Bouchecareilh M, Alitalo Ok, Li DY, Bikfalvi A, et al. Blocking Fibroblast Progress Issue receptor signaling inhibits tumor progress, lymphangiogenesis, and metastasis. PLoS ONE. 2012;7:e39540.
Brzozowa M, Wojnicz R, Kowalczyk-Ziomek G, Helewski Ok. The Notch ligand Delta-like 4 (DLL4) as a goal in angiogenesis-based most cancers remedy? Contemp Oncol (Pozn). 2013;17:234–7.
Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF remedy in vivo. Most cancers Res. 2011;71:6073–83.
Oon CE, Bridges E, Sheldon H, Sainson RCA, Jubb A, Turley H, et al. Position of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour progress. Oncotarget. 2017;8:40115–31.
Garajova I, Giovannetti E, Biasco G, Peters GJ. c-Met as a Goal for Personalised Remedy. Transl Oncogenom. 2015;7:13–31.
Razzak M. Focused therapies: hepatocyte progress factor-a perpetrator of drug resistance. Nat Rev Clin Oncol. 2012;9:429.
Nakagawa T, Matsushima T, Kawano S, Nakazawa Y, Kato Y, Adachi Y, et al. Lenvatinib together with golvatinib overcomes hepatocyte progress issue pathway-induced resistance to vascular endothelial progress issue receptor inhibitor. Most cancers Sci. 2014;105:723–30.
Zhou L, Liu XD, Solar M, Zhang X, German P, Bai S, et al. Focusing on MET and AXL overcomes resistance to sunitinib remedy in renal cell carcinoma. Oncogene. 2016;35:2687–97.
Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, et al. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Transforming in Non-Small Cell Lung Most cancers. Clin Most cancers Res. 2017;23:5489–501.
Chen W, Wu J, Shi H, Wang Z, Zhang G, Cao Y, et al. Hepatic stellate cell coculture permits sorafenib resistance in Huh7 cells via HGF/c-Met/Akt and Jak2/Stat3 pathways. Biomed Res Int. 2014;2014:764981.
Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, et al. HGF/c-Met acts in its place angiogenic pathway in sunitinib-resistant tumors. Most cancers Res. 2010;70:10090–100.
Scholz A, Harter PN, Cremer S, Yalcin BH, Gurnik S, Yamaji M, et al. Endothelial cell-derived angiopoietin-2 is a therapeutic goal in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol Med. 2016;8:39–57.
Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, et al. Randomized, double-blind, placebo-controlled section II examine of AMG 386 mixed with weekly paclitaxel in sufferers with recurrent ovarian most cancers. J Clin Oncol. 2012;30:362–71.
Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, et al. Focusing on the ANG2/TIE2 axis inhibits tumor progress and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Most cancers Cell. 2011;19:512–26.
Cumpanas AA, Cimpean AM, Ferician O, Ceausu RA, Sarb S, Barbos V, et al. The Involvement of PDGF-B/PDGFRbeta Axis within the Resistance to Antiangiogenic and Antivascular Remedy in Renal Most cancers. Anticancer Res. 2016;36:2291–5.
Ishii Y, Hamashima T, Yamamoto S, Sasahara M. Pathogenetic significance and chance as a therapeutic goal of platelet derived progress issue. Pathol Int. 2017;67:235–46.
Demoulin JB, Essaghir A. PDGF receptor signaling networks in regular and most cancers cells. Cytokine Progress Issue Rev. 2014;25:273–83.
Appelmann I, Liersch R, Kessler T, Mesters RM, Berdel WE. Angiogenesis inhibition in most cancers remedy: platelet-derived progress issue (PDGF) and vascular endothelial progress issue (VEGF) and their receptors: organic features and function in malignancy. Latest Outcomes Most cancers Res. 2010;180:51–81.
Dmitrieva OS, Shilovskiy IP, Khaitov MR, Grivennikov SI. Interleukins 1 and 6 as Most important Mediators of Irritation and Most cancers. Biochemistry (Mosc). 2016;81:80–90.
Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, et al. An interleukin-17-mediated paracrine community promotes tumor resistance to anti-angiogenic remedy. Nat Med. 2013;19:1114–23.
Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Most cancers Res. 2010;70:1063–71.
Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, et al. Interleukin-12: organic properties and medical software. Clin Most cancers Res. 2007;13:4677–85.
Yang B, Kang H, Fung A, Zhao H, Wang T, Ma D. The function of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm. 2014;2014:623759.
Xi HQ, Wu XS, Wei B, Chen L. Eph receptors and ephrins as targets for most cancers remedy. J Cell Mol Med. 2012;16:2894–909.
Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, et al. Ephrin-B2 regulates VEGFR2 operate in developmental and tumour angiogenesis. Nature. 2010;465:487–91.
Depner C, Zum Buttel H, Bogurcu N, Cuesta AM, Aburto MR, Seidel S, et al. EphrinB2 repression via ZEB2 mediates tumour invasion and anti-angiogenic resistance. Nat Commun. 2016;7:12329.
Cunha SI, Pietras Ok. ALK1 as an rising goal for antiangiogenic remedy of most cancers. Blood. 2011;117:6999–7006.
de Vinuesa AG, Bocci M, Pietras Ok, Ten Dijke P. Focusing on tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 operate. Biochem Soc Trans. 2016;44:1142–9.
Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, Lappin P, et al. Focusing on activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis via a mechanism of motion complementary to anti-VEGF therapies. Most cancers Res. 2011;71:1362–73.
Gore AV, Swift MR, Cha YR, Lo B, McKinney MC, Li W, et al. Rspo1/Wnt signaling promotes angiogenesis through Vegfc/Vegfr3. Growth. 2011;138:4875–86.
Pereira C, Schaer DJ, Bachli EB, Kurrer MO, Schoedon G. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a goal for the antiinflammatory motion of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol. 2008;28:504–10.
Dailey W, Shunemann R, Yang F, Moore M, Knapp A, Chen P, et al. Variations in activation of intracellular signaling in major human retinal endothelial cells between isoforms of VEGFA 165. Mol Vis. 2021;27:191–205.
Plyukhova AA, Budzinskaya MV, Starostin KM, Rejdak R, Bucolo C, Reibaldi M, et al. Comparative Security of Bevacizumab, Ranibizumab, and Aflibercept for Remedy of Neovascular Age-Associated Macular Degeneration (AMD): A Systematic Overview and Community Meta-Evaluation of Direct Comparative Research. J Clin Med. 2020;9:1–14.
Sales space BJ, Ramakrishnan B, Narayan Ok, Wollacott AM, Babcock GJ, Shriver Z, et al. Extending human IgG half-life utilizing structure-guided design. MAbs. 2018;10:1098–110.
Bajardi-Taccioli A, Blum A, Xu C, Sosic Z, Bergelson S, Feschenko M. Impact of protein aggregates on characterization of FcRn binding of Fc-fusion therapeutics. Mol Immunol. 2015;67:616–24.
Chen X, Zaro JL, Shen W-C. Fusion protein linkers: property, design and performance. Adv Drug Deliv Rev. 2013;65:1357–69.
Brysbaert G, Mauri T, de Ruyck J, Lensink MF. Identification of Key Residues in Proteins By Centrality Evaluation and Flexibility Prediction with RINspector. Curr Protoc Bioinform. 2019;65:e66.
